Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01552343 · ClinicalTrials.gov registry record · Phase 3
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
A Phase 3 study of Nocturia, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT01552343 is a Phase 3 study of Nocturia that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 56 participants, below the 310-participant average among 9 other Nocturia trials with a reported enrollment target (82% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT01552343, a Phase 3 study of Nocturia, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI scores (sensitivity of the NI total score to change in nocturia). To assess which NI diary items account for the main difference in change in total NI score in treatment versus placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Desmopressin
Study Locations (10)
Florida
- South Florida Medical Research - Aventura
- Avail Clinical Research, LLC - DeLand
Michigan
- Beyer Research - Kalamazoo
- Remedica LLC - Rochester
Texas
- Quality Research, Inc. - San Antonio
- Radiant Research, Inc. - San Antonio
Illinois
- Accelovance - Peoria
Massachusetts
- DM Clinical Research - Springfield
New York
- Accumed Research Associates - Garden City
South Carolina
- Radiant Research, Inc. - Greer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01552343
The ClinicalTrials.gov registry entry for NCT01552343 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 9 other Nocturia trials with a reported enrollment target (82% lower). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nocturia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01552343 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Florida, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT01552343 about?
NCT01552343 is a clinical study titled "Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary". The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI scores (sensitivity of the NI total score to change in nocturia). To asse...
What is the current status of trial NCT01552343?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2012-03. Estimated completion is 2012-06.
What conditions does trial NCT01552343 study?
This clinical trial studies the following conditions: Nocturia.
What interventions are being tested in trial NCT01552343?
The interventions under investigation include: Placebo (DRUG), Desmopressin (DRUG).
Who is sponsoring clinical trial NCT01552343?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01552343 being conducted?
This trial has 10 study locations across Florida, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nocturia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
COMPLETED · Phase 3
-
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
COMPLETED · Phase 3
-
Long Term Safety Assessment of SER120 in Patients With Nocturia
COMPLETED · Phase 3
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
RECRUITING · Phase 4
-
Multi-center Trial to Improve Nocturia and Sleep in Older Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.